Skip to Content

Anthim Approval History

  • FDA approved: Yes (First approved March 18th, 2016)
  • Brand name: Anthim
  • Generic name: obiltoxaximab
  • Dosage form: Injection
  • Company: Elusys Therapeutics, Inc.
  • Treatment for: Anthrax Prophylaxis, Anthrax

Anthim (obiltoxaximab) is a monoclonal antibody (mAb) anthrax antitoxin for the treatment and prevention of inhalational anthrax.

Inhalation anthrax is considered to be the most deadly form of anthrax. It is caused by breathing in spores of the anthrax bacteria Bacillus anthracis, which when inhaled, replicate and produce a potentially lethal toxin. Anthim works by preventing entry of the toxin into susceptible cells, reducing spread, and limiting tissue damage.

Anthim was approved under the FDA's Animal Rule, which allows efficacy findings from animal studies when it is not feasible or ethical to conduct efficacy trials in humans.

Anthim is indicated for the treatment of anthrax in combination with appropriate antibacterial drugs (levofloxacin, ciprofloxacin and doxycycline), and is administered as a single-dose intravenous infusion. Hypersensitivity reactions, including anaphylaxis, have been reported during infusion, and premedication with diphenhydramine is recommended. The most common side effects reported in healthy volunteers who participated in the safety studies were headache, itching, upper respiratory tract infections, cough, nasal congestion, urticaria, pain in extremities, and bruising, swelling and pain at the infusion site.

Development History and FDA Approval Process for Anthim

DateArticle
Mar 21, 2016Approval FDA Approves Anthim (obiltoxaximab) for Inhalation Anthrax
Jun  1, 2015FDA Accepts Biologics License Application for Anthim (Obiltoxaximab)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide